Overview of CheckMate Trials 648 and 649
CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment.
KEYNOTE-590 Trial Impacting Treatment Landscape for ESCC and Upper GI Cancer
Syma Iqbal, MD, provides an overview of the KEYNOTE-590 trial and its impact on treatment pathways for ESCC and GI cancers.
Closing Thoughts on CKD Management
The esteemed panel concludes with their final thoughts on CKD therapies and management.
Continued Health Disparities Seen in Practice
Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.
Payer Considerations Impacted by Updated ATS Guidelines
Paul Noble, MD, provides his closing thoughts on payer perspectives surrounding ILD, as well as considerations for the trajectory of ILD treatment landscape.
Conditional Recommendation of Nintedanib and Use in ILD Treatment
Nintedanib recommendations for use from the recent ATS guidelines and treatment implementation are considered by Paul Noble, MD.
Prognostic Models Optimizing MDS Treatment Pathways
Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.
Incidence and Prevalence of MDS Across Patient Populations
Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.
Patient Engagement Strategies to Increase Biosimilar Uptake
Sonia Oskouei explores the managed care landscape and opportunities for increasing biosimilar uptake to improve patient care.
Evolving Treatment Landscape for Upper GI and Esophageal Cancer
Evolving treatment strategies for esophagogastric cancer are explored by Syma Iqbal, MD, including unmet needs across the treatment landscape.
Prevalence and Characteristics of GI Cancers
Syma Iqbal, MD, provides insights pertaining to various types of upper GI cancers, as well as primary characteristics and risk factors for these diseases.
Non-JAK Inhibitor Therapy Options Available for Vitiligo Treatment
Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.
Safety Considerations for Vitiligo-Focused Drug Therapies
Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.
Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment
Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.
Combination Therapy and Payer Perspective on CKD Therapies
Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.
Using Published Data to Consider SGLT2 Inhibitors and MRAs in CKD Management
Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.
Utilizing Pirfenidone in ILD Treatment Strategy
Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.
FDA-Approved Treatment Options for ILD
ILD treatment options approved by the FDA are explored by Dr Noble, MD.
MDS Impacting Patient Quality of Life
Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.
Defining Myelodysplastic Syndrome
A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).
Role of JAK Inhibitors in Treatment of Vitiligo
Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.
Unmet Needs in Vitiligo Treatment Landscape
The panel navigates unmet needs surrounding the vitiligo treatment landscape.
Identifying Unmet Needs Surrounding Patients With Heart Failure
The panel of experts provide their final insights regarding unmet needs surrounding treatment management of heart failure.
Patient and Provider Perceptions Surrounding Affordability for HF Treatments
Experts share their thoughts on payer and provider perceptions surrounding affordable HF care, as well as strategies to manage care-associated costs.
Navigating Multidisciplinary HF Treatment With Multiple Comorbidities
Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.
Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data
IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.
Gaining Confidence With a Switching Study
Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.
Treatment Landscape Surrounding Anti-Fibrotic Agents
Dr Noble, MD provides and overview of the treatment landscape surrounding ILD, specifically examining IPF, PPF, and SSc-ILD antifibrotic therapy.
ATS Guideline Updates in Treatment Paradigms for ILD
Dr Paul Noble, MD discusses updates and changes in ATS-directed guidelines for the treatment of ILD.
The Role of MRAs in CKD and CV Treatment
Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.
